A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance bacillus Calmette-Guerin therapy

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

The aim of the trial is to determine whether Hyperthermia plus the chemotherapy drug mitomycin is an effective therapy for patients with non-muscle invasive bladder cancer who have tumour recurrence following bacillus Calmette-Guerin (BCG) therapy. To do this we will be looking at disease-free survival in all patients; and the complete response rate after three months of treatment for those patients who entered the trial with Carcinoma In-Situ (a difference form of non-muscle invasive bladder cancer).

Critère d'inclusion

Non-Muscle-Invasive Bladder Cancer

Liens

ictrp
euctr

Kusajili – Centralise les essais cliniques mondiaux

A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive blad...